High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Autor: Karin Rydström, Heidi Nurmi, Sari Riihijärvi, Sirpa Leppä, Magnus Björkholm, Mikael Eriksson, Harald Holte, Lars Moller Pedersen, Øystein Fluge, Mats Jerkeman
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Oncology
Adult
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Adolescent
Phases of clinical research
Gene Expression
Kaplan-Meier Estimate
Biology
03 medical and health sciences
chemistry.chemical_compound
Young Adult
0302 clinical medicine
Chemoimmunotherapy
immune system diseases
Internal medicine
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Prospective Studies
Prospective cohort study
030304 developmental biology
Aged
0303 health sciences
Hematology
General Medicine
Exons
Middle Aged
medicine.disease
Prognosis
3. Good health
Lymphoma
Vascular endothelial growth factor
Vascular endothelial growth factor A
chemistry
030220 oncology & carcinogenesis
Cancer research
Female
Immunotherapy
Lymphoma
Large B-Cell
Diffuse
Diffuse large B-cell lymphoma
Signal Transduction
Zdroj: Riihijärvi, S, Nurmi, H, Holte, H, Björkholm, M, Fluge, O, Pedersen, L M, Rydström, K, Jerkeman, M, Eriksson, M & Leppä, S 2012, ' High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy ', European Journal of Haematology, vol. 89, no. 5, pp. 395-402 . https://doi.org/10.1111/ejh.12005
DOI: 10.1111/ejh.12005
Popis: Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients
Databáze: OpenAIRE
Externí odkaz: